Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity

European Journal of Cancer

Volumn 38, Issue 14, 2002, Pages 1832-1837

  Cavaletti, G ^a,c   Zanna, C ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Sigma Tau SpA   (Italy)

^c Clinica Neurologica AO S Gerardo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ALKYLATING AGENT; ALPHA TOCOPHEROL; AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; DIMESNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; LETEPRINIM; LEUKEMIA INHIBITORY FACTOR; LEVACECARNINE; LITHIUM; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PACLITAXEL; SOMATOMEDIN C; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE; WR 2771; XALIPRODEN;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PARESTHESIA; PRIORITY JOURNAL; REVIEW;

EID: 0036711432     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00229-0     Document Type: Article

References (54)

1. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249:2002;9-17.
2. Connelly E., Markman M., Kennedy A.et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers. unexpected incidence of neurotoxicity Gynecol. Oncol. 62:1996;166-168.
3. De Vita V.T. Jr., Hellmann S., Rosemberg S.A. Cancer. Principles and Practice of Oncology. 5th edn. 1997;Philadelphia, Lippincott-Raven.
4. Rose P.G., Blessing J.A., Gershenson D.M., McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix. a gynecologic oncology group study J. Clin. Oncol. 17:1999;2676-2680.
5. Hamers F.P., Pette C., Neijt J.P., Gispen W.H. The ACTH-(4-9) analog, ORG 2766 prevents taxol-induced neuropathy in rats. Eur. J. Pharmacol. 233:1993;177-178.
6. van der Hoop G.R., Hamers F.P., Neijt J.P.et al. Protection against cisplatin induced neurotoxicity by ORG 2766. histological and electrophysiological evidence J. Neurol. Sci. 126:1994;109-115.
7. van der Hoop G.R., Vecht C.J., van der Burg M.E.L.et al. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N. Engl. J. Med. 322:1990;89-94.
8. Roberts J.A., Jenison E.L., Kim K.et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol. Oncol. 67:1997;172-177.
9. Kemp G., Rose P., Lurain J.et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities. results of a randomized control trial in patients with advanced ovarian cancer J. Clin. Oncol. 14:1996;2101-2112.
10. Selvaggi G., Belani C.P. Carboplatin and paclitaxel in non-small cell lung cancer. the role of amifostine Semin. Oncol. 26(Suppl. 7):1999;51-60.
11. Cavaletti G., Minoia C., Schieppati M., Tredici G. Protective effects of glutathione in cisplatin neurotoxicity in rats. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;771-776.
12. Tedeschi M., De Cesare A., Oriana S.et al. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. Cancer Treat. Rev. 18:1991;253-259.
13. Cascinu S., Cordella L., Del Ferro E.et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer. a randomized double-blind placebo-controlled trial J. Clin. Oncol. 13:1995;26-32.
14. Smyth J.F., Bowman A., Perren T.et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin. results of a double-blind, randomised trial Ann. Oncol. 8:1997;569-573.
15. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol (in press).
16. Boyle F.M., Beatson C., Monk R.et al. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother. Pharmacol. 48:2001;429-434.
17. Kurek J. AM424. history of a novel drug candidate Clin. Exp. Pharmacol. Physiol. 27:2000;553-557.
18. Turner M.R., Parton M.J., Leigh P.N. Clinical trials in ALS. an overview Semin. Neurol. 21:2001;167-175.
19. Apfel S.C., Arezzo J.C., Lewis M.E., Kessler J.A. The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice. Ann. N. Y. Acad. Sci. 692:1993;243-245.
20. Gao W.-Q., Dybdal N., Shinsky N.et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. 38:1995;30-37.
21. Pradat P.F., Finiels F., Kennel P.et al. Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum. Gene Ther. 12:2001;367-375.
22. Gill J.S., Windebank A.J. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J. Clin. Inv. 101:1998;2842-2850.
23. Konings P.N.M., Makkink W.K., van Delft A.M.L., Ruigt G.S.F. Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res. 640:1994;195-204.
24. Malgrange B., Delrée P., Rigo J.M.et al. Image analysis of neurite regeneration by adult rat dorsal root ganglion neurons in culture. quantification of the neurotoxicity of anticancer agents and its prevention by nerve growth factor or fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3 J. Neurosci. Meth. 53:1994;111-122.
25. De Santis S., Pace A., Bove L.et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin. Canc. Res. 6:2000;90-95.
26. Aloe L., Manni L., Properzi F.et al. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin. behavioral, structural and biochemical analysis Auton. Neurosci. 86:2000;84-93.
27. Apfel S.C., Arezzo J.C., Lipson L.A., Kessler J.A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 31:1992;76-80.
28. Schmidt Y., Unger I., Bartke R., Reiter R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (cd/db) mice. Exp. Neurol. 132:1995;16-23.
29. Tredici G., Braga M., Nicolini G.et al. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp. Neurol. 159:1999;551-558.
30. Apfel S.C., Lipton R.B., Arezzo J.C., Kessler J.A. Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol. 29:1991;87-90.
31. Cavaletti G, Pezzoni G, Pisano C, et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett 2002, 322, 103-106.
32. Apfel S.C., Kessler J.A., Adornato B.T.et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 51:1998;695-702.
33. Simivic D., Isner J.M., Ropper A.H.et al. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch. Neurol. 58:2001;761-768.
34. Nitta A., Ogihara Y., Onishi J.et al. Oral administration of propentofylline, a stimulator of nerve growth factor (NGF) synthesis, recovers cholinergic neuronal dysfunction induced by the infusion of anti-NGF antibody into the rat septum. Behav. Brain Res. 83:1997;201-204.
35. Saita K., Ohi T., Hanaoka Y.et al. Effect of 4-methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental acrylamide-induced neuropathy in rats. Neurotoxicol. 16:1995;403-412.
36. Fritz I.B., Yue K.T.N. Long chain carnitine acyltransferase and the role of acylcarnitine derivatives in the catalytic increase of fatty acid oxidation induced by carnitine. J. Lipid Res. 4:1963;279.
37. Bieber L.L. Carnitine. Ann. Rev. Biochem. 57:1988;261-283.
38. Lowitt S., Malone J.I., Salem A.F.et al. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metab. Clin. Exp. 44:1995;677-680.
39. Di Giulio A.M., Lesma E., Gorio A. Diabetic neuropathy in the rat. 1. ALCAR augments the reduced levels and axoplasmic transport of substance P J. Neurosci. Res. 40:1995;414-419.
40. Kano M., Kawakami T., Hori H.et al. Effects of ALCAR on the fast axoplasmic transport in cultured sensory neurons of streptozotocin-induced diabetic rats. Neurosci. Res. Mar. 33:1999;207-213.
41. Piovesan P., Pacifici L., Taglialatela G.et al. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 633:1994;77-82.
42. Foreman P.J., Perez-Polo J.R., Angelucci L.et al. Effects of acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;117-133.
43. Pisano C., Vesci L., Bellucci A.et al. Acetyl-L-carnitine protects from peripheral neuropathy and reduces bone marrow injury in taxol-treated mice. Proc. Am. Assoc. Cancer Res. 41:2000;607.
44. Tredici G, Marmiroli P, Zoia C, et al. Relationship between acetyl-L-carnitine and nerve growth factor: results of in vitro and in vivo neuroprotection studies. J. Neurol. 2002 249(Suppl. 1), 28.
45. Maestri A, De Pasquale Ceratti A, Calandri C, et al. Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Am Soc Clin Oncol 2002, 21, 2476.
46. Boyle F.M., Wheeler H.R., Shenfield G.M. Glutamate ameliorates experimental vincristine neuropathy. J. Pharm. Exp. Ther. 279:1996;410-415.
47. Vahdat L., Papadopoulos K., Lange D.et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin. Cancer Res. 7:2001;1192-1197.
48. Foreman M, Taylor EM, Jenkins S, et al. Effects of AIT-082 (Neotrofin™) on peripheral neuropathy induced by vincristine treatments in rats. In Proc AACR-NCI-EORTC Int Conference, Miami, 2001.
49. Cavalletti E., Cavaletti G., Tredici G.et al. Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in wistar rats. Proc. Am. Assoc. Cancer Res. 40:1999;398.
50. Hausheer F., Cavaletti G., Tredici G.et al. Oral and intravenous BNP7787 protects against platinum neurotoxicity without in vitro and in vivo tumor protection. Proc. 90th Am. Assoc. Cancer Res. 40:1999;398.
51. Petrini M., Vaglini F., Cervetti G.et al. Is lithium able to reverse neurological damage induced by vinca alkaloids? J. Neural. Transm. 106:1999;569-575.
52. Bove L., Picardo M., Maresca V., Jandolo B., Pace A. A pilot study on the relationship between cisplatin neuropathy and vitamin E. J. Exp. Clin. Cancer Res. 20:2001;277-280.
53. Turner M.R., Parton M.J., Leigh P.N. Clinical trials in ALS. an overview Semin. Neurol. 21:2001;167-175.
54. Campana W.M., Eskeland N., Calcutt N.A.et al. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology. 19:1998;237-244.